Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia
Not Applicable
Completed
- Conditions
- Bone Fibrous Dysplasia
- Interventions
- Biological: Blood sampling
- Registration Number
- NCT02868645
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
Fibrous dysplasia is a rare bone disease which can cause pain and fractures. It has been shown that periostin is over expressed in fibrous component in patients bones ; but periostin has never been measured out in serum of patients, although it is easy to assess. This study aims to show whether serum periostin is elevated in serum of patients with fibrous dysplasia, and if it is more elevated in patients with severe forms of the disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 65
Inclusion Criteria
- patients with fibrous dysplasia of the bone
- access to social security
- informed consent
Read More
Exclusion Criteria
- no informed consent
- pregnancy
- patients with a history of conditions known to increase periostin serum (stade IV cancer, severe asthma, pulmonary fibrosis...)
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Patients with bone fibrous dysplasia Blood sampling Patients with bone fibrous dysplasia will have a blood sampling to assess periostin rate in serum
- Primary Outcome Measures
Name Time Method Periostin rate in serum At inclusion
- Secondary Outcome Measures
Name Time Method Periostin rate in serum in patients with Mac Cune Albright syndrome At inclusion Periostin rate in serum according to the number of fibrotic bones At inclusion Periostin rate in serum in patients with severe phenotype of the disease At inclusion
Trial Locations
- Locations (1)
Service de rhumatologie Pavillon F - Hôpital Edouard Herriot
🇫🇷Lyon cedex 03, France